BioCopy raises CHF 9 M

BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany. The company has closed a CHF 9 million tranche of its Series A round to fund the preclinical studies needed to file an IND for its lead candidate.

Announced on
Round
Series A
Amount
CHF 9 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

The investors were not named in the announcement.

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic